Sobi to streamline nirsevimab contractual arrangements
Nirsevimab economics simplified through a new royalty agreement with Sanofi and the termination of the participation agreement with AstraZeneca Alignment will provide Sobi benefit through simplification, only revenue recognition and greater flexibility Sobi® today announced a streamlining and simplification of the contractual economics for nirsevimab. In January 2019, Sobi completed the acquisition of Synagis® (palivizumab) from AstraZeneca in the US as well as the right to AstraZeneca’s full share of US profits and losses for nirsevimab. Synagis is a medicine used to help